2020 has not been kind to Sanofi’s flagship heartburn medication Zantac. When reports first surfaced of contamination of the medication with a known carcinogen, attention immediately turned to the labs that made ranitidine, the active ingredient in Zantac. It wasn’t until researchers discovered that Zantac could be producing the carcinogen itself that calls began for a recall of the drug. The mechanism that could lead to such an occurrence, however, has ...
Zantac, Ranitidine, NDMA, and You: What You Need to Know
Posted April 9, 2020 in Drug and Medical Device Lawsuits | Heartburn Medications and Kidney Damage | Product News and Recalls | Recall
Zantac Carcinogen Lawsuits Consolidated into Multidistrict Litigation
Posted February 28, 2020 in Drug and Medical Device Lawsuits | Product News and Recalls
As the number of lawsuits filed over NDMA contaminated Zantac continues to grow, over 140 such suits have been sent to a federal judge to be heard as a multidistrict litigation. The MDL will be the first for U.S. District Judge Robin Rosenberg who serves as a judge for the Southern District of Florida. In selecting Judge Rosenberg, the Judicial Panel on Multidistrict Litigation called her “an ...
Zantac May Produce Harmful Carcinogen on Its Own
Posted February 4, 2020 in Drug and Medical Device Lawsuits | Product News and Recalls
New concerns are emerging over the presence of a known carcinogen in the compound used to make heartburn medication Zantac. Things have taken an interesting twist however, as researchers explore the possibility that the source of the contamination may be the Zantac itself.
The issue of NDMA contamination in Zantac and other drugs based on its main ingredient first came to light last year. That was when ...
continue reading...NDMA Contamination Found in Additional Blood Pressure and Diabetes Medications
Posted January 10, 2020 in Drug and Medical Device Lawsuits | Product News and Recalls
Plaintiffs in valsartan-based drug lawsuits filed over possible carcinogenic contamination may have to make room for additional consumers as lawyers push for the inclusion of two other blood pressure medications, losartan and irbesartan. Batches of the drugs, in addition to valsartan, have been found to be tainted with NDMA, or nitrosodimethylamine. NDMA is a known human carcinogen and has been linked to the development of certain ...
Things have quickly gone from bad to worse for GlaxoSmithKline and its popular heartburn medication Zantac. And it all began thanks to the care and caution of an online pharmacy; not a government regulator.
The pharmacy, Valisure, tests all the medications it makes available to its customers itself. And it was that testing; not that of the FDA or any other government entity tasked with keeping its citizens safe, that ...
continue reading...Update: Consolidation Sought in Valsartan Lawsuits
Posted November 23, 2018 in Drug and Medical Device Lawsuits | Product News and Recalls
Plaintiffs involved in lawsuits over contamination of a key ingredient in generic heart medications have moved to have their cases consolidated before a federal judge.
Shipments of valsartan, an ingredient in medications used to treat high blood pressure and heart failure, were found to be tainted with a chemical known as NDMA. According to the EPA, NDMA is a possible human carcinogen and is used in ...
continue reading...
